Open AccessLongitudinal PET Imaging to Monitor Treatment Efficacy by Liposomal Irinotecan in Orthotopic Patient-Derived Pancreatic Tumor Models of High and Low Hypoxia
Author(s) -
Manuela Ventura,
Nicholas Bernards,
Raquel De Souza,
Inga B. Fricke,
Bart S. Hendriks,
Jonathan B. Fitzgerald,
Helen Lee,
Stephan G. Klinz,
Jinzi Zheng
Publication year - 2019
Publication title -
molecular imaging and biology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.846
H-Index - 68
eISSN - 1860-2002
pISSN - 1536-1632
DOI - 10.1007/s11307-019-01374-x
Subject(s) - hypoxia (environmental) , irinotecan , tumor hypoxia , medicine , pancreatic tumor , pancreatic cancer , magnetic resonance imaging , positron emission tomography , colorectal cancer , nuclear medicine , cancer research , pathology , radiology , cancer , radiation therapy , chemistry , oxygen , organic chemistry
Hypoxia is linked to aggressiveness, resistance to therapy, and poor prognosis of pancreatic tumors. Liposomal irinotecan (nal-IRI, ONIVYDE®) has shown potential in reducing hypoxia in the HT29 colorectal cancer model, and here, we investigate its therapeutic activity and ability to modulate hypoxia in patient-derived orthotopic tumor models of pancreatic cancer.